Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2011-06-14
2011-06-14
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000
Reexamination Certificate
active
07959909
ABSTRACT:
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4636463 (1987-01-01), Altman et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4855238 (1989-08-01), Gray et al.
patent: 4921699 (1990-05-01), DeChiara et al.
patent: 4929554 (1990-05-01), Goeddel et al.
patent: 5096705 (1992-03-01), Goeddel et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208158 (1993-05-01), Bech et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5574137 (1996-11-01), Gray et al.
patent: 5582824 (1996-12-01), Goeddel et al.
patent: 5595888 (1997-01-01), Gray et al.
patent: 5690925 (1997-11-01), Gray et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 6046034 (2000-04-01), Waschutza et al.
patent: 6497871 (2002-12-01), Gray et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6753165 (2004-06-01), Cox et al.
patent: 7038015 (2006-05-01), Jensen
patent: 7148333 (2006-12-01), Cox, III
patent: 7153943 (2006-12-01), Cox, III et al.
patent: 7214779 (2007-05-01), Cox, III
patent: 7232885 (2007-06-01), Cox, III
patent: 7253267 (2007-08-01), Cox, III
patent: 7270809 (2007-09-01), Cox, III
patent: 7306931 (2007-12-01), Rosendahl et al.
patent: 7309781 (2007-12-01), Cox, III
patent: 7314921 (2008-01-01), Cox, III
patent: 7345149 (2008-03-01), Cox, III
patent: 7345154 (2008-03-01), Cox, III
patent: 7399839 (2008-07-01), Cox, III
patent: 2003/0166865 (2003-09-01), Cox, III
patent: 2004/0136955 (2004-07-01), Barker et al.
patent: 2004/0230040 (2004-11-01), Cox
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 2005/0214254 (2005-09-01), Cox
patent: 2007/0111240 (2007-05-01), Cox
patent: 2007/0253929 (2007-11-01), Cox et al.
patent: 2008/0076706 (2008-03-01), Cox
patent: 2008/0219950 (2008-09-01), Cox
patent: 2009/0060863 (2009-03-01), Cox
patent: 2066370 (1996-04-01), None
patent: 0243153 (1987-10-01), None
patent: 0355460 (1990-02-01), None
patent: 0458064 (1991-11-01), None
patent: 02-234692 (1990-09-01), None
patent: 04-164098 (1992-09-01), None
patent: 4-507099 (1992-12-01), None
patent: 5-268983 (1993-10-01), None
patent: 6-510904 (1994-12-01), None
patent: 9-503396 (1997-04-01), None
patent: 10-507080 (1998-07-01), None
patent: WO 87/01132 (1987-02-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 90/13310 (1990-11-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 93/06217 (1993-04-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/12638 (1994-06-01), None
patent: WO 94/12639 (1994-06-01), None
patent: WO 94/22466 (1994-10-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 95/034326 (1995-12-01), None
patent: WO 96/04385 (1996-02-01), None
patent: WO 96/11949 (1996-04-01), None
patent: WO 96/31537 (1996-10-01), None
patent: WO 96/36362 (1996-11-01), None
patent: WO 97/11370 (1997-03-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 98/37200 (1998-08-01), None
Walter M.R. et al. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature. 2000. vol. 376, p. 230-235.
U.S. Appl. No. 12/001,639, Rosendahl et al., Dec. 11, 2007.
Watson JD, Molecular biology of the Gene 3rd edition, p. 337, W. A. Benjamin, Inc. Menlo Park, California, Reading, Massachusetts, London, Amsterdam, Don Mills, Ontario. Sydney, 1977, ISBN 0-8053-9609-8.
Bazan et al., Science, vol. 257 No. 5068, pp. 410-413 (Jul. 1992).
Bazan, Immunology Today, 11:350-354 (1990).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Campbell et al., J. Peptide Res., 49:527-537 (1997).
Cunningham BC, Wells JA. Science. 244:1081-5, (1989).
Cunningham et al., Science, 243:1330-1336 (1989).
DeChiara, T.M. et al., “Procedures for in Vitro DNA Mutagenesis of Human Leukocyte Interferon Sequences.” Methods in Enzymology, vol. 119(58). pp. 403-415. (1986).
Evinger et al., J. Biol. Chem. 256(5):2113-2114 (1981).
Goodson and Katre, Bio/Technology, 8:343-346 (1990).
Mott and Campbell, Curr Opin Struct Biol, 5:114-121 (1995).
Olins P.O. et al: ‘Saturation muatgenesis of human interleukin-3’ Journal of Biological Chemistry vol. 270, No. 40, Oct. 6, 1996, pp. 23754-23760.
Valenzuela D. et al., “Is Sequence Conservation in Interferons Due to Selection for Functional Proteins.” Nature, vol. 313(21). pp. 698-700. Feb. 1985.
Wells, Ann. Rev. Biochem., 65:609-634 (1996).
Zurawaki et al. “Definition and spatial location of mouse interleukin-2 residues that interact with the heterotrmeric receptor”, Embo Journal 12, 5113-5119, 1993.
International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US98/14497, mailed May 11, 1999 (4152-1-PCT).
International Search Report for International (PCT) Patent Application No. PCT/US98/14497, mailed Oct. 22, 1998 (4152-1-PCT).
Chene et al. “Crystallization of the Complex of Human IFN-gamma and the Extracellular Domain of the IFN-gamma Receptor.” Proteins: Structure, Function, and Genetics: 23:591-594 (1995).
Sprang and Bazan, Curr. Opin. Struct. Biol., 3:815-827 (1993).
Ealick et al. “Three-dimensional structure of recombinant human interferon-gamma.”, Science. May 3, 1991;252(5006):698-702.
Watson JD-Molecular Biology of the gene, third edition, WA Benjamin, eds. ISBN 0-8053-9609-8, p. 367, 1977.
Cheetham et al., “Structure-function studies of human interferons-α: enhanced activity on human and murine cells”, Antiviral Research 15 (1991) 27-39.
Olins P.O. et al: ‘Saturation muatgenesis of human interleukin-3’ Journal of Biological Chemistry vol. 270, No. 40, Oct. 6, 1995, pp. 23754-23760.
Ishikawa et al., “The Substitution of Cysteine 17 of Recombinant Human G-CSF with Alanine Greatly Enhanced its Stability,” Cell Structure and Function, 1992, vol. 17(1), pp. 61-65.
Official Action for Australian Patent Application No. 2008203051, dated Aug. 30, 2010.
U.S. Appl. No. 12/502,839, Cox et al., Jul. 14, 2009.
U.S. Appl. No. 12/604,165, Cox, Oct. 22, 2009.
U.S. Appl. No. 12/610,891, Cox, Nov. 2, 2009.
Alberts et ai, The birth, assembly and death of proteins. Chapter 5 in Molecular biology of the cell, Third edition, Garland Publishing, Inc. New York, NY, 1994; ISBN 0-8153-1619-4.
Cosenza et al. “Disulfide Bond Assignment in Human Interleukin-7 by Matrix-assisted Laser Desorption/Ionization Mass Spectroscopy and Site-directed Cysteine to Serine Mutational Analysis” The Journal of Biological Chemistry, vol. 272, No. 52, Issue of Dec. 26, pp. 32995-33000, 1997.
Edge et al., “Interferon Analogues from Synthetic Genes: An Approach to Protein Structure-Activity Studies”, Interferon, vol. 7, pp. 1-46, 1986.
Kroemer et al. Prediction of three-dimensional structure of IL-7 by homology modeling, Protein Engineering, 9,493-498, 1996.
Lydon et al., “Immunochemical Mapping of α-2 Interferon”, Biochemistry 1985, 24, 4131-4141.
Senda et al., “Refined crystal structure of recombinant murine interferon-beta at 2.15 A resolution.”, J. Mol. Biol., 1995, vol. 253, pp. 187-207.
Takahashi et al. “Short stature caused by a mutant growth hormone with an antagonistic effect.”, Endocr J. Oct. 1996;43 Suppl:S27-32. Abstract only, PMID
Bolder Biotechnology Inc.
Hissong Bruce D
Landsman Robert
Sheridan & Ross P.C.
LandOfFree
Cysteine variants of interferon gamma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine variants of interferon gamma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine variants of interferon gamma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672714